Tag: BDX008,Opdivo,PD-1 axis blockade,PD-1 blockade therapy,PD-L1,Press Releases,nivolumab
-
Investigational Blood Test Identifies Patients with Melanoma Who Are More Likely to Have Improved Survival on Nivolumab Therapy; Biodesix’ blood test is independent of PD-L1 expression
Biodesix, Inc. today announced new clinical findings showing that its novel investigational test, BDX008, based on profiling serum proteins, identifies patients with advanced melanoma who are more likely to have longer progression-free and overall survival with nivolumab therapy.[1] Early data suggesting the test’s clinical potential for guiding anti-PD-1 therapy is being presented at the 30th…